GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.20
Ask: 5.30
Change: 0.00 (0.00%)
Spread: 0.10 (1.923%)
Open: 5.20
High: 5.30
Low: 5.20
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Sabien works with Empiric; Coro sells in Italy

Mon, 27th Mar 2023 18:42

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Sabien Technology Group PLC - technology company, focused on the heating, cooling and transportation sectors - Completes work with Empiric Student Property PLC to help the student accommodation provider's goals to become net zero by 2033. "Sabien's M2G business, Sabien Technology Ltd, which focuses on CO2 mitigation devices for commercial boilers, has been working with its mutual partner, Amber Energy Solutions Ltd, over the last six months to install equipment across eight properties in Empiric's portfolio to reduce CO2 emissions," Sabien says "Empiric Student Property has also adopted Sabien's M2G cloud connect solution to support the delivery of energy efficiencies and cost savings across these properties, as well as the monitoring of longer-term energy use with the potential for further system optimisation opportunities."

----------

Coro Energy PLC - South East Asia-focused energy - Signs deal for disposal of Italian assets to Zodiac Energy PLC for up to EUR7.5 million. Initial cash payment of EUR1.5 million to be made to Coro within seven working days. Proposed disposal needs shareholder approval at general meeting scheduled for April 25. Coro says: "The company remains primarily focused on Southeast Asia and the significant growth and investment opportunities the region provides. In expectation of near term and long awaited developments on the Duyung PSC and the company's renewable portfolio in Southeast Asia and with a view to capturing the value inherent in the Italian Portfolio following gas price rises, the [sale purchase agreement] was concluded with Zodiac, with the consideration then being available to deploy in line with the stated strategy.

----------

Anglo Asian Mining PLC - Azerbaijan-focused gold, copper and silver producer - Lauds data at Garadag deposit. Findings confirm potential of asset to produce over 300,000 tonnes of copper. Anglo Asian adds: "This initial assessment by the company has not been prepared according to the JORC standard. The company intends to prepare a mineral resource estimate using the JORC procedures on completion of the evaluation programme, targeting mid-2024 for the preparation of the mineral resource estimate according to the JORC code."

----------

Global Petroleum Ltd - oil & gas exploration in Africa and the Mediterranean - Reports updated prospective resources estimate for PEL0094 licence in offshore Namibia. Company has 78% working interest in asset and serves as operator. Reports unrisked gross prospective resources of 3.5 million barrels of oil at asset, up from 3.3 million previously. "As the initial conclusion from our further technical work, we are pleased to report the very significant increase in prospective resources - as well as the improved risking - for our primary prospect, Marula. This, together with the supporting technical detail, will now be communicated to potential farm-in partners," company adds.

----------

Clean Power Hydrogen PLC - Doncaster, England-based green hydrogen technology and manufacturing company - New Zealand-based partner Fabrum Solutions Ltd receives order an order from construction firm Obayashi Corp for delivery of MFE220 unit. "The order represents Fabrum's first customer under CPH2's manufacturing agreement for which CPH2 will receive a technology fee as well as revenue from the sale of key components including CPH2 stacks," Clean Power says.

----------

AEW UK REIT PLC - real estate investment trust for UK regional commercial property - Acquires freehold retail warehousing unit in Bamber Bridge, Preston for GBP6.5 million. Asset is single-let to retailer Matalan Retail Ltd with over nine year left on lease. "Matalan is known to trade strongly from the location, with the store being one of its top 10 performers, as well as being the retailer's first ever store in the U.K. The lease benefits from a 2027 rent review to the higher of open market value, or 2.5% per annum compounded, resulting in a minimum reversionary yield of 10.7%," AEW UK REIT says.

----------

Jade Road Investments Ltd - Hong Kong-based investment firm - Says manager Harmony Capital Investors Ltd will advise firm on orderly disposal of investments it currently owns, a batch of assets it labels as "legacy portfolio". "HCIL shall, subject to the overall supervision and control of the board, also undertake general administrative, investor relations, marketing, portfolio management and risk management functions for the company," Jade Road says. Instead of an annual management fee, HCIL is to now be paid a fixed fee of USD350,000 for services connected to disposals. Jade Road adds: "This represents a substantial reduction in fees as compared to the previous agreement." Executive Chair John Croft says: "In line with the recent change to our investment policy and refocus of the company, we remain committed to the orderly disposal of our legacy portfolio. The revised services agreement with HCIL has been negotiated to provide a better alignment with the company's current objectives. This agreement reflects the importance that the board places on achieving exits from its China and other Asia based investments so that surplus cash can be deployed into its revised investment strategy."

----------

Allergy Therapeutics PLC - biotechnology company focused on the treatment and diagnosis of allergic disorders - Patients dosed in phase 1 of Protect trial probing novel peanut allergy vaccine candidate VLP Peanut.

----------

Tristel PLC - Cambridgeshire-based maker of infection prevention, contamination control and hygiene products - Submits additional data requested by the US Food & Drug Administration ahead of decision on Duo ULT high-level disinfectant. Decision is expected before end of second quarter of 2023. Tristel says: "The FDA will now commence its final review of the De Novo submission and the agency's internal rules require it to make its decision by the company's financial year-end. The FDA approval will enable Duo's use for high-level disinfection of intra-cavity ultrasound probes. Duo is already approved by the US Environmental Protection Agency for use on skin-surface ultrasound transducers."

----------

Nuformix PLC - London-based pharmaceutical development company - Says data finds NXP002, designed to treat lung-scarring condition idiopathic pulmonary fibrosis, is "well tolerated in ex-vivo human lung tissue". Ex-vivo refers to outside of the body. "NXP002 alone delivers a strong, consistent anti-fibrotic effect as demonstrated by modulation of the release of multiple biomarkers of fibrosis," company adds. "Overall, the results provide further support of NXP002's potential to increase efficacy of existing therapies with the benefits of inhaled delivery."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Sep 2019 11:26

Allergy Therapeutics Looking To Chinese Market As It Swings To Profit

Allergy Therapeutics Looking To Chinese Market As It Swings To Profit

Read more
27 Jun 2019 10:07

Allergy Therapeutics earnings set to top expectations

(Sharecast News) - Biotechnology group Allergy Therapeutics told investors on Thursday that 2019 full-year earnings looked set to come in ahead of market expectations.

Read more
19 Jun 2019 13:39

Allergy Therapeutics Hires Former Advanced Medical Solutions CFO

(Alliance News) - Allergy Therapeutics PLC on Wednesday said it has appointed Mary Tavener as a non-executive director with immediate effect.The biotechnology company said Tavener has in 19

Read more
20 May 2019 13:42

Allergy Therapeutics Vaccine Helps Dust Mite Allergy Symptoms In Study

LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said its Acarovac MPL vaccine improved dust mite allergy symptoms during a phase one study.The AM101 study, which was open-label

Read more
20 May 2019 11:00

Allergy Therapeutics flags positive outcomes from recent treatment trial

(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive Phase 1 safety and tolerability results of subcutaneous 'Acarovac MPL' (monophosphoryl lipid A) in patients with house dust mite-induced allergic rhinoconjunctivitis on Monday.

Read more
25 Apr 2019 10:01

Allergy Therapeutics eyes 2020 start for hay fever inoculation trials

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics will kick off phase III trials of its short-course inoculation for grass pollen-induced hay fever in the second half of 2020 following a successful round of meetings with German and American regulatory bodies.

Read more
18 Mar 2019 10:44

WINNERS & LOSERS SUMMARY: Footasylum Rises On "Generous" JD Offer

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - Tinto, up 2.3%, Group, up in

Read more
18 Mar 2019 10:06

Allergy Therapeutics Surprised As Vaccine Trial Fails Primary Endpoint

LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said a phase three trial of its birch pollen allergy vaccine did not meet its primary endpoint.Shares in Allergy Therapeutics 43%

Read more
18 Mar 2019 08:51

Allergy Therapeutics shares plunge after disappointing clinical trial

(Sharecast News) - Shares in biotechnology company Allergy Therapeutics were plunging on Monday morning, after it announced disappointing top-line results from the phase 3 clinical trial 'B301' of its new adjuvanted birch allergoid product.

Read more
6 Mar 2019 11:13

Allergy Therapeutics Interim Profit Rises 67% On Higher Revenue

LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday reported significantly higher profit for the first six months of its financial year as revenue rose and research costs were the to of

Read more
6 Mar 2019 10:19

Allergy Therapeutics profits rise as it spends less on R&D

(Sharecast News) - Specialty pharmaceutical group Allergy Therapeutics announced its unaudited interim results for the six months ended 31 December on Wednesday, reporting a 10.6% improvement in revenue on both a reported and constant currency basis, to £46.7m.

Read more
16 Jan 2019 12:26

Allergy Therapeutics First Half Meets Forecasts On European Growth

LONDON (Alliance News) - Allergy immunology vaccines developer Allergy Therapeutics PLC said Wednesday trading in the first half was in line with expectations.Allergy Therapeutics expects -

Read more
16 Jan 2019 08:51

Allergy Therapeutics sees good first-half progress

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market for the six months ended 31 December on Wednesday, reporting that it was trading in line with board expectations.

Read more
27 Nov 2018 13:12

Allergy Therapeutics Continues To Perform Well, Revenue Up "Strongly"

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday it has continued to perform well, with revenue up "strongly" from the prior year and sales in line with market financial to

Read more
27 Nov 2018 10:05

Allergy Therapeutics boosted by strong German performance

(Sharecast News) - Biotechnology company Allergy Therapeutics has seen revenues increase throughout the first half of its trading year thanks to an improved market share for its allergy vaccines on the continent.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.